The short version of LY3437943 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
==== Sarcomas ==== Connective tissue malignancies, sarcomas, are rare in the oral mucosa. Osteosarcoma, chondrosarcoma arise in bone and cartilage, lymphoma in haematological disorders. The most common malignancies are carcinomas, overwhelmingly squamous cell carcinoma.
Specifically, the FDA found a lack of efficacy for stanozolol as "an adjunct to promote body tissue-building processes and to reverse tissue-depleting processes in such conditions as malignant diseases and chronic nonmalignant diseases; debility in elderly patients, and other emaciating diseases; gastrointestinal disorders resulting in alterations of normal metabolism; use during pre-operative and postoperative periods in undernourished patients and poor-risk surgical cases due to traumatism; use in infants, children, and adolescents who do not reach an adequate weight; supportive treatment to help restore or maintain a favorable metabolic balance, as in postsurgical, postinfectious, and convalescent patients; of value in pre- operative patients who have lost tissue from a disease process or who have associated symptoms, such as anorexia; retention and utilization of calcium; surgical applications; gastrointestinal disease, malnourished adults, and chronic illness; pediatric nutritional problems; prostatic carcinoma; and endocrine deficiencies." The FDA gave Sterling six months to stop marketing stanozolol for the indications for which there was no evidence for efficacy, and one year to submit further data for the two indications for which it found probable efficacy. In August and September 1970, Sterling submitted more data; the data was not sufficient but the FDA allowed the drug to continue to be marketed, since there was an unmet need for drugs for osteoporosis and pituitary dwarfism, but Sterling was required to submit more data.
28 February to 28 February 1971 The 11th Light Infantry Brigade launched Operation Iron Mountain to attack PAVN/VC bases and logistics routes in southeastern Quảng Ngãi Province. The operation resulted in 4,589 PAVN/VC killed and 137 captured while U.S. losses are 440 killed.
The agent caused permanent harm, with effects that included "chronic weakness in his arms, a toxic hepatitis that gave rise to cirrhosis of the liver, epilepsy, spells of severe depression, and an inability to read or concentrate that left him totally disabled and unable to work." He never recovered and, after five years of deteriorating health, died in July 1992. The use of a fast-acting peripheral anticholinergic drug such as atropine can block the receptors where acetylcholine acts to prevent poisoning (as in the treatment for poisoning by other acetylcholinesterase inhibitors). Atropine, however, is difficult to administer safely, because its effective dose for nerve agent poisoning is close to the dose at which patients suffer severe side effects, such as changes in heart rate and thickening of the bronchial secretions, which fill the lungs of someone suffering nerve agent poisoning so that suctioning of these secretions, and other advanced life support techniques, may be necessary in addition to administration of atropine to treat nerve agent poisoning. In the treatment of nerve agent poisoning, atropine is most often administered along with a Hagedorn oxime such as pralidoxime, obidoxime, TMB-4, or HI-6, which reactivates acetylcholinesterase which has been inactivated by phosphorylation by an organophosphorus nerve agent and relieves the respiratory muscle paralysis caused by some nerve agents.
characterizes the potential for initial spread of an infectious person in a naive population, assuming the change in the susceptible population is negligible during the initial spread. A linear system of ODEs can always be described by a matrix. So, the next step is to construct a linear positive operator that provides the next generation of infected people when applied to the present generation. Note that this operator (matrix) is responsible for the number of infected people, not all the compartments. Iteration of this operator describes the initial progression of infection within the heterogeneous population. So comparing the spectral radius of this operator to unity determines whether the generations of infected people grow or not.
Sources: en.wikipedia.org
18 June: The New Zealand Government announces the scrapping of the five-yearly national census. The Māori iwi (tribe) Te Patutokotoko files legal action against Conservation Minister Tama Potaka and the Department of Conservation for not consulting them about granting ten-year concessions to Whakapapa Holdings Limited and Pure Tūroa to run the Tūroa and Whakapapa skifields. New World's Victoria Park supermarket in Auckland is extensively damaged during a major fire. 19 June – The New Zealand Government confirms it suspended NZ$20 million of core sector support funding to the Cook Islands in early June 2025 in retaliation for the Cook Islands government signing a partnership agreement with China without consulting New Zealand, per the requirements of their free association relationship. 20 June Prime Minister Christopher Luxon meets with Chinese President Xi Jinping in Beijing to discuss strengthening bilateral tourism, education and agricultural trade. The New Zealand Symphony Orchestra announces simultaneously the scheduled conclusion of the tenure of Gemma New as its artistic director and principal conductor in 2027, and the appointment of André de Ridder as its new music director, effective in 2027. 21 June – Brian Tamaki's Destiny Church stages a march in Auckland's Aotea Square opposing the spread of non-Christian religions and immigration in New Zealand. Destiny Church's actions are denounced by Minister for Ethnic Communities Mark Mitchell.
Conduction velocity The speed at which an action potential travels along a nerve fiber. It is influenced by factors such as axon diameter and myelination. Consciousness A state of awareness of self and the environment. In neuroscience, it involves the coordinated activity of multiple brain regions, particularly the thalamocortical system. Corpus callosum The largest white matter structure in the brain, consisting of a thick band of axons that connects the left and right cerebral hemispheres. Cortical column A vertically organized group of neurons in the cerebral cortex that processes the same type of information, such as orientation or location in space. It is a basic functional unit of the cortex. Cortical plasticity The ability of the cerebral cortex to adapt and reorganize in response to experience, learning, or injury. Corticospinal tract A major descending pathway from the motor cortex to the spinal cord that mediates voluntary motor control, especially fine movements of the limbs. Creutzfeldt–Jakob disease (CJD) A rare and fatal neurodegenerative disorder caused by misfolded prion proteins. It leads to rapid cognitive decline, motor dysfunction, and ultimately death. Critical period A developmental window during which the nervous system is particularly sensitive to certain environmental stimuli, crucial for proper development of functions such as vision and language. Cross modal plasticity The ability of one sensory modality to reorganize and compensate in another’s absence (e.g., visual cortex being recruited for touch in individuals who are blind).
Advanced age, although OSA occurs in neonates, as with Pierre Robin syndrome, and in all age groups of people. Brain injury (temporary or permanent), although this does not account for the 99% of OSA patients who have normal brains and normal lives. Decreased muscle tone caused by drugs or alcohol, or caused by neurological disorders. This also would not account for the majority of people with OSA. Long-term snoring, which is postulated to potentially induce local nerve lesions in the soft tissues of the pharynx. Snoring may produce traumatic vibrations that may give rise to nerve injuries in the upper airway muscles, further contributing to OSA. Increased soft tissue around the airway, often resulting from obesity, though not seen in all patients with OSA. Some otorhinolaryngologists believe the risk factors to be structural features that give rise to a narrowed airway, such as enlarged tonsils, an enlarged posterior tongue, or fat deposits in the neck. Further factors leading to OSA can be impaired nasal breathing, floppy soft palate, or a collapsible epiglottis. Some oral and maxillofacial surgeons believe the risk factors to be several primary forms of mandibular hypoplasia, which offer a primary anatomical basis to the development of OSA through glossoptosis. Some maxillofacial surgeons who offer orthognathic surgery for treatment of OSA believe that their treatments offer superior guarantees of a cure.
=== Variation === The sternalis muscle may be a variant form of the pectoralis major or the rectus abdominis. Some fibers are occasionally connected with the costoxiphoid ligaments, and the side of the xiphoid process.
Sources: en.wikipedia.org
Instead, it is suggested "that desmosine may be more useful in understanding the pathogenesis of ALI and less useful as a marker of disease severity.” The current standard for measuring lung disease progression, for example, is measured through the forced expiratory volume in one second (FEV1) compared to the maximum lung capacity; in other words, the volume of air a person can exhale from full lungs in one second compared to their maximum lung capacity. This method, while simple and physiologically thorough, has biological limitations, and so a superior biological marker is being sought after. Desmosine has been studied as one such biological marker, with studies in the 1980s to link urinary desmosine concentration with elastin breakdown in the lungs. Though large amounts of data have been collected with regards to desmosine's potential as a replacement biological marker in determining disease progression, some believe there is still insufficient evidence for desmosine to meet and fill this need. In orthopedics, one study examined equine tendons and how their increasing stiffness and fatigue with age was due to fragmentation of the elastin in the tendons. The superficial digital flexor tendon (SDFT) and the common digital extensor tendon (CDET) were analyzed for elastin composition, comparing older tendons to younger ones.
=== Hardware === The technology made by Dionex includes the Rapid Separation LC (RSLC) and polymeric HPLC columns, a type of monolithic HPLC column. Unlike the inorganic silica columns, the polymer monoliths are made of an organic polymer base. Dionex, traditionally known for its ion chromatography capabilities, has led this side of the field. Dionex first acquired a license for the polymeric monolith technology in the 1990s. Dionex also acquired ESA Biosciences' HPLC assets in 2009, expanding its expertise in this area.
Shahid holds that the Tanukh entered the Gharb as Sunni Muslims and afterward became Druze. Their leaders in the Gharb may have received and embraced the Fatimid Isma'ili da'wa (mission) as early as the late 10th century. In the 11th century, the Tanukhids of Mount Lebanon inaugurated the Druze community in Lebanon, when most of them accepted and adopted the new message, due to their leadership's close ties with then Fatimid caliph al-Hakim bi-Amr Allah. In the 14th century, the central parts of Mount Lebanon were described as a Tanukhid stronghold, housing both Druze and Shiite Muslims. Members of the Tanukhids in Mount Lebanon include Al-Sayyid al-Tanukhi, a prominent 15th century Druze theologian and commentator; and Muhammad bin al-Muwaffaq al-Tanukhi, an emir and Shiite Muslim who lived in the 13th century.
Eukaryotic cells were created some 2.2 billion years ago in a process called eukaryogenesis. This is widely agreed to have involved symbiogenesis, in which an archaean and a bacterium came together to create the first eukaryotic common ancestor. It evolved into a population of single-celled organisms that included the last eukaryotic common ancestor, gaining capabilities along the way. This cell had a new level of complexity, with a nucleus and facultatively aerobic mitochondria. It featured at least one centriole and cilium, sex (meiosis and syngamy), peroxisomes, and a dormant cyst with a cell wall of chitin and/or cellulose. The last eukaryotic common ancestor gave rise to the eukaryotes' crown group, containing the ancestors of animals, fungi, plants, and a diverse range of single-celled organisms. The green plants were created around 1.6 billion years ago with a second episode of symbiogenesis that added chloroplasts, derived from cyanobacteria.
For Survivor Series on November 18, a "winner takes all" 10-man tag team match was announced; Austin captained a team consisting Angle, Shane McMahon, Van Dam, and Booker T, against Team WWF; captained by The Rock, the team also included Jericho, Kane, The Undertaker and Big Show. At Survivor Series, Angle sided with the WWF, helping The Rock to hit the Rock Bottom and pin Austin to win the match, marking the end of the Invasion storyline. The following night on Raw, Vince McMahon decided he was going to strip Austin of the championship and award it to Angle, before Ric Flair returned and announced he was now co-owner of the WWF. Austin returned moments after this announcement and attacked Angle and McMahon for their actions. He was then handed his championship belt by Flair and celebrated with him in the ring, turning him face once again. At Vengeance on December 9, a tournament was held to unify the WWF Championship and the WCW World Heavyweight Championship, held by The Rock; also involving Angle and Jericho. Austin would defeat Angle, before losing the unification match to Jericho following interference by McMahon and Booker T.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.